Complexes with S‐Donor Ligands, 4. Mono‐ and Di‐Homo‐ and ‐Hetero‐Nuclear Gold(I), Silver(I), and Palladium(II) Complexes with 2‐(Methylthio)pyridine, Pyridine‐2(1H)‐thione, and Benzoxazole‐2(3H)‐thione. Some Examples of the Use of Complexes as Ligands

Abstract

AgClO4 reacts with bidentate ligands 2‐(methylthio)pyridine (SMepy) or complexes PPN[Au(Spy)2] [PPN = N(PPh3)2, HSpy = pyridine‐2(1H)‐thione) or PPN[Au(Sbz)2] (HSbz = benzoxazole‐2(3H)‐thione), themselves acting as ligands, to give dinuclear complexes [Ag2(μ‐SMepy)2](ClO4)2 (1), [AgAu(μ‐Spy)2] (2), or [AgAu(μ‐Sbz)2] (3), respectively. By treating 1 with [AuCl(tht)] (tht = tetrahydrothiophene), [Au(SMepy)(tht)]ClO4 (4) is obtained which, in turn, reacts with SMepy to give [Au(SMepy)2]ClO4 (5). Similarly, [PdCl2(NCPh)2] reacts with SMepy in 1:1 molar ratio to give [Pd2Cl2(μ‐Cl)2(SMepy)2] (6) which reacts with SMepy in 1:2 molar ratio to give [PdCl2(SMepy)2] (7). On the other hand, HSpy reacts with Ag2CO3 to give [Ag2(μ‐Spy)2] (8), and (SMepyH)ClO4 reacts with [Au(acac)PPh3] (acacH = acetyl‐acetone) to give [Au(SMepy)PPh3]ClO4 (9).

Inhibition of lipoxygenase (LOX) and anticancer activity caused by gold(I) mixed ligands complexes of triphenylphosphine and thioamides

“…Many gold(III) and gold(I) compounds were tested for their anti-tumour activity against various cancerous cell lines 3 and the results also have been, reviewed 4 . A reason for the anti-tumour investigation of gold compounds is related to the square-planar geometry, also found for platinum in cisplatin, since gold(III) is isoelectronic with platinum(II) [2][3][4] . Given the generally reducing mammalian environment, compounds containing gold(III) may be expected to be reduced in vivo to gold(I) and this led to the investigation of possible anti-tumour properties of gold(I) compounds [2][3][4] .…”

“…A reason for the anti-tumour investigation of gold compounds is related to the square-planar geometry, also found for platinum in cisplatin, since gold(III) is isoelectronic with platinum(II) [2][3][4] . Given the generally reducing mammalian environment, compounds containing gold(III) may be expected to be reduced in vivo to gold(I) and this led to the investigation of possible anti-tumour properties of gold(I) compounds [2][3][4] . The relationship between polyunsaturated fatty acid (such as linoleic or arachidonic acids) metabolism by enzymes like lipoxygenase (LOX) or cyclooxygenase (COX), inflammation and carcinogenesis, has been extensively examined in numerous pharmacological studies [5][6][7] .…”

“…Auronofin (triethylphosphine-gold(I) thioglugose (Et3PAuTg)) and its second generation drug Ridaura TM (triethylphosphine(2,3,4,6-tetra-acetyl-glycopyrasonato-S-)gold(I)), an extensively gold(I) anti-arthritic drug in use, were found to be highly cytostatic to tumour cells and active against i.p. P388 leukaemia 2 . Many gold(III) and gold(I) compounds were tested for their anti-tumour activity against various cancerous cell lines 3 and the results also have been, reviewed 4 .…”

Gold(I) Thiolates as Metalloligands for the Synthesis of the First Zirconocene−Gold Complexes

“…[15] Their preparation usually starts from gold(III), in the form of sodium tetrachloroaurate(III) or the corresponding acid, which then requires a reduction step. Bishop et al [16] described the synthesis of [Au(SCH 2 COOH)] using ethyl 2-hydroxyethyl sulfide as reducing agent.…”

Synthesis, structural characterization and biological study of new organotin(IV), silver(I) and antimony(III) complexes with thioamides

“…Thiolato gold(I) complexes such as commercial antiarthritics myocrisin allochrysin solganol or auronofin are among the most important anti-arthritics [13]. In addition auronofin was found to be highly toxic to tumor cells and active against i.p.P388 leukemia while solganol has in vitro inhibitory effects on human immunodeficiency Virus 1 which is the etiological agent of AIDS [14][15][16]. Thioamides may coordinate to a metal ion with a variety of coordination modes including: (i) mono-dentate, (ii) chelating, (iii) bi-dentate, (iv) bridging, (v) tri-dentate, and (vi) polydentate (Scheme 1).…”